Lung transplantation in IIP: A review

Respirology

Volumn 21, Issue 7, 2016, Pages 1173-1184

  Brown, A Whitney ^a   Kaya, Hatice ^b   Nathan, Steven D ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

idiopathic pulmonary fibrosis; interstitial lung disease; lung transplantation; survival; treatment outcome

Indexed keywords

AIRWAY OBSTRUCTION; BRONCHOMALACIA; CHRONIC LUNG ALLOGRAFT DYSFUNCTION; CORONARY ARTERY DISEASE; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; GRAFT DYSFUNCTION; HUMAN; INTERSTITIAL PNEUMONIA; LUNG CANCER; LUNG TRANSPLANTATION; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; ORGAN SIZE; OUTCOME ASSESSMENT; POSTOPERATIVE INFECTION; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ASPIRATION; PULMONARY VASCULAR DISEASE; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING;

EID: 84987662350     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12691     Document Type: Review

References (90)

1. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–748.
2. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Lund LH, Meiser B et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014: focus theme: retransplantation. J. Heart Lung Transplant. 2014; 33: 1009–1024.
3. Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla R, Leseche G, Fournier M. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126: 469–475.
4. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769.
5. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.
6. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–2092.
7. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221–229.
8. Brown AW, Shlobin OA, Weir N, Albano MC, Ahmad S, Smith M, Leslie K, Nathan SD. Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis. Chest 2012; 142: 1005–1010.
9. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531–537.
10. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.
11. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 459–466.
12. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP 3rd et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 543–548.
13. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 1084–1090.
14. Swigris JJ, Swick J, Wamboldt FS, Sprunger D, du Bois R, Fischer A, Cosgrove GP, Frankel SK, Fernandez-Perez ER, Kervitsky D et al. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2009; 136: 841–848.
15. Hook JL, Arcasoy SM, Zemmel D, Bartels MN, Kawut SM, Lederer DJ. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39: 359–365.
16. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962–969.
17. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156: 684–691.
18. Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest 2015; 147: 173–179.
19. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am. J. Respir. Crit. Care Med. 2002; 166: 839–842.
20. Stern JB, Mal H, Groussard O, Brugiere O, Marceau A, Jebrak G, Fournier M. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest 2001; 120: 213–219.
21. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG et al. A consensus document for the selection of lung transplant candidates: 2014-An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2015; 34: 1–15.
22. Kneidinger N, Holzborn J, Czerner S, Weig T, Behr J, Winter H, Neurohr C, Schramm R. Evaluation of short-term outcome after lung transplantation in the lung allocation score era. Thorac. Cardiovasc. Surg. 2014.
23. Egan TM, Murray S, Bustami RT, Shearon TH, McCullough KP, Edwards LB, Coke MA, Garrity ER, Sweet SC, Heiney DA et al. Development of the new lung allocation system in the United States. Am. J. Transplant. 2006; 6(5 Pt 2): 1212–1227.
24. Kilic A, Merlo CA, Conte JV, Shah AS. Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score? J. Thorac. Cardiovasc. Surg. 2012; 144: 1133–1138.
25. Grossman RF, Frost A, Zamel N, Patterson GA, Cooper JD, Myron PR, Dear CL, Maurer J. Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. N. Engl. J. Med. 1990; 322: 727–733.
26. Meyers BF, Lynch JP, Trulock EP, Guthrie T, Cooper JD, Patterson GA. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J. Thorac. Cardiovasc. Surg. 2000; 120: 99–107.
27. Meyer DM, Edwards LB, Torres F, Jessen ME, Novick RJ. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann. Thorac. Surg. 2005; 79: 950–957, discussion 7-8.
28. Nathan SD, Shlobin OA, Ahmad S, Burton NA, Barnett SD, Edwards E. Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. J. Heart Lung Transplant. 2010; 29: 1165–1171.
29. Hadjiliadis D, Angel LF. Controversies in lung transplantation: are two lungs better than one? Semin. Respir. Crit. Care Med. 2006; 27: 561–566.
30. Force SD, Kilgo P, Neujahr DC, Pelaez A, Pickens A, Fernandez FG, Miller DL, Lawrence C. Bilateral lung transplantation offers better long-term survival, compared with single-lung transplantation, for younger patients with idiopathic pulmonary fibrosis. Ann. Thorac. Surg. 2011; 91: 244–249.
31. Weiss ES, Allen JG, Merlo CA, Conte JV, Shah AS. Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis. Ann. Thorac. Surg. 2009; 88: 1616–1625, discussion 25-6.
32. De Oliveira NC, Osaki S, Maloney J, Cornwell RD, Meyer KC. Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation. Interact. Cardiovasc. Thorac. Surg. 2012; 14: 263–267.
33. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 659–664.
34. Barnard JB, Davies O, Curry P, Catarino P, Dunning J, Jenkins D, Sudarshan C, Nair S, Tsui S, Parmar J. Size matching in lung transplantation: an evidence-based review. J. Heart Lung Transplant. 2013; 32: 849–860.
35. Miyoshi S, Schaefers HJ, Trulock EP, Yamazaki F, Schreinemakers H, Patterson GA, Cooper J. Donor selection for single and double lung transplantation. Chest size matching and other factors influencing posttransplantation vital capacity. Chest 1990; 98: 308–313.
36. Miyoshi S, Demertzis S, Eckstein F, Hohlfeld J, Schaefers HJ. Chest size matching in single and double lung transplantation. Jpn. J. Thorac. Cardiovasc. Surg. 1999; 47: 163–170.
37. Keyser RE, Woolstenhulme JG, Chin LM, Nathan SD, Weir NA, Connors G, Drinkard B, Lamberti J, Chan L. Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. J Cardiopulm. Rehabil. Prev. 2015; 35: 47–55.
38. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135: 442–447.
39. Bermudez CA, Richards T, Shigemura N, Bhama J, Sappington P, Crespo M, Morell M, Pilewski J, D'Cunha J. Contemporary outcomes of lung transplantation in patients with preoperative extracorporeal membrane oxygenation: a propensity-match analysis. J. Heart Lung Transplant. 2014; 33: S29.
40. Lafarge M, Mordant P, Thabut G, Brouchet L, Falcoz PE, Haloun A, Le Pimpec-Barthes F, Maury JM, Reynaud-Gaubert M, Saint-Raymond C et al. Experience of extracorporeal membrane oxygenation as a bridge to lung transplantation in France. J. Heart Lung Transplant. 2013; 32: 905–913.
41. Javidfar J, Brodie D, Iribarne A, Jurado J, Lavelle M, Brenner K, Arcasoy S, Sonett J, Bacchetta M. Extracorporeal membrane oxygenation as a bridge to lung transplantation and recovery. J. Thorac. Cardiovasc. Surg. 2012; 144: 716–721.
42. Saggar R, Khanna D, Vaidya A, Derhovanessian A, Maranian P, Duffy E, Belperio JA, Weigt SS, Dua S, Shapiro SS et al. Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax 2014; 69: 123–129.
43. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann. Intern. Med. 2013; 158: 641–649.
44. King CS, Khandhar S, Burton N, Shlobin OA, Ahmad S, Lefrak E, Barnett SD, Nathan SD. Native lung complications in single-lung transplant recipients and the role of pneumonectomy. J. Heart Lung Transplant. 2009; 28: 851–856.
45. Ahmad S, Shlobin OA, Nathan SD. Pulmonary complications of lung transplantation. Chest 2011; 139: 402–411.
46. King RC, Binns OA, Rodriguez F, Kanithanon RC, Daniel TM, Spotnitz WD, Tribble CG, Kron IL. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann. Thorac. Surg. 2000; 69: 1681–1685.
47. Christie JD, Kotloff RM, Pochettino A, Arcasoy SM, Rosengard BR, Landis JR, Kimmel SE. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 1232–1241.
48. Christie JD, Sager JS, Kimmel SE, Ahya VN, Gaughan C, Blumenthal NP, Kotloff RM. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127: 161–165.
49. Fiser SM, Kron IL, McLendon Long S, Kaza AK, Kern JA, Tribble CG. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J. Heart Lung Transplant. 2001; 20: 631–636.
50. de Perrot M, Bonser RS, Dark J, Kelly RF, McGiffin D, Menza R, Pajaro O, Schueler S, Verleden GM, ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J. Heart Lung Transplant. 2005; 24: 1460–1467.
51. Barr ML, Kawut SM, Whelan TP, Girgis R, Bottcher H, Sonett J, Vigneswaran W, Follette DM, Corris PA, ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers. J. Heart Lung Transplant. 2005; 24: 1468–1482.
52. Whitson BA, Nath DS, Johnson AC, Walker AR, Prekker ME, Radosevich DM, Herrington CS, Dahlberg PS. Risk factors for primary graft dysfunction after lung transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131: 73–80.
53. Fang A, Studer S, Kawut SM, Ahya VN, Lee J, Wille K, Lama V, Ware L, Orens J, Weinacker A et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011; 139: 782–787.
54. Robertson AG, Ward C, Pearson JP, Corris PA, Dark JH, Griffin SM. Lung transplantation, gastroesophageal reflux, and fundoplication. Ann. Thorac. Surg. 2010; 89: 653–660.
55. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G,. IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir. Med. 2013; 1: 369–376.
56. Raghu G. Idiopathic pulmonary fibrosis: increased survival with ‘gastroesophageal reflux therapy’: fact or fallacy? Am. J. Respir. Crit. Care Med. 2011; 184: 1330–1332.
57. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE 2nd, Pellegrini CA. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006; 27: 136–142.
58. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129: 794–800.
59. Li B, Hartwig MG, Appel JZ, Bush EL, Balsara KR, Holzknecht ZE, Collins BH, Howell DN, Parker W, Lin SS et al. Chronic aspiration of gastric fluid induces the development of obliterative bronchiolitis in rat lung transplants. Am. J. Transplant. 2008; 8: 1614–1621.
60. Palmer SM, Miralles AP, Howell DN, Brazer SR, Tapson VF, Davis RD. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 2000; 118: 1214–1217.
61. Hartwig MG, Anderson DJ, Onaitis MW, Reddy S, Snyder LD, Lin SS, Davis RD. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann. Thorac. Surg. 2011; 92: 462–468, discussion; 8-9.
62. Hoppo T, Jarido V, Pennathur A, Morrell M, Crespo M, Shigemura N, Bermudez C, Hunter JG, Toyoda Y, Pilewski J et al. Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation. Arch. Surg. 2011; 146: 1041–1047.
63. Machuzak M, Santacruz JF, Gildea T, Murthy SC. Airway complications after lung transplantation. Thorac. Surg. Clin. 2015; 25: 55–75.
64. Woodrow JP, Shlobin OA, Barnett SD, Burton N, Nathan SD. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J. Heart Lung Transplant. 2010; 29: 1159–1164.
65. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J. Heart Lung Transplant. 2014; 33: 127–133.
66. Todd JL, Jain R, Pavlisko EN, Finlen Copeland CA, Reynolds JM, Snyder LD, Palmer SM. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am. J. Respir. Crit. Care Med. 2014; 189: 159–166.
67. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, Wagnetz D, Chaparro C, Singer LG, Hutcheon MA et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J. Heart Lung Transplant. 2011; 30: 735–742.
68. Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, Waddell TK, Singer LG, Hutcheon MA, Keshavjee S et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod. Pathol. 2013; 26: 350–356.
69. Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Waddell TK, Singer LG, Hutcheon MA, Keshavjee S et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur. Respir. J. 2014; 44: 1479–1503.
70. Haider Y, Yonan N, Mogulkoc N, Carroll KB, Egan JJ. Bronchiolitis obliterans syndrome in single lung transplant recipients—patients with emphysema versus patients with idiopathic pulmonary fibrosis. J. Heart Lung Transplant. 2002; 21: 327–333.
71. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, Schoonis A, Nawrot TS, Dupont LJ, Verleden GM. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur. Respir. J. 2011; 37: 164–172.
72. Wahidi MM, Ravenel J, Palmer SM, McAdams HP. Progression of idiopathic pulmonary fibrosis in native lungs after single lung transplantation. Chest 2002; 121: 2072–2076.
73. Yang D, Wilson JM, Bai C, Yee J, Wilcox PG, Khalil N, Levy RD. Acute exacerbation of pulmonary fibrosis following single lung transplantation. Can. Respir. J. 2012; 19: e3–4.
74. Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest 2003; 123: 1758–1763.
75. Nathan SD, Shlobin OA, Ahmad S, Barnett SD, Burton NA, Gladwin MT, Machado RF. Pulmonary hypertension in patients with bronchiolitis obliterans syndrome listed for retransplantation. Am. J. Transplant. 2008; 8: 1506–1511.
76. Kizer JR, Zisman DA, Blumenthal NP, Kotloff RM, Kimmel SE, Strieter RM, Arcasoy SM, Ferrari VA, Hansen-Flaschen J. Association between pulmonary fibrosis and coronary artery disease. Arch. Intern. Med. 2004; 164: 551–556.
77. Izbicki G, Ben-Dor I, Shitrit D, Bendayan D, Aldrich TK, Kornowski R, Kramer MR. The prevalence of coronary artery disease in end-stage pulmonary disease: is pulmonary fibrosis a risk factor? Respir. Med. 2009; 103: 1346–1349.
78. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, Burton N, Barnett SD. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir. Med. 2010; 104: 1035–1041.
79. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am. J. Respir. Crit. Care Med. 2008; 178: 1257–1261.
80. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 2000; 161: 5–8.
81. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, Patz EF Jr, Swensen SJ, Society Fleischner. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237: 395–400.
82. De Oliveira NC, Osaki S, Maloney JD, Meyer KC, Kohmoto T, D'Alessandro AM, Love RB. Lung transplantation with donation after cardiac death donors: long-term follow-up in a single center. J. Thorac. Cardiovasc. Surg. 2010; 139: 1306–1315.
83. Snell GI, Levvey BJ, Oto T, McEgan R, Pilcher D, Davies A, Marasco S, Rosenfeldt F. Early lung transplantation success utilizing controlled donation after cardiac death donors. Am. J. Transplant. 2008; 8: 1282–1289.
84. Mason DP, Murthy SC, Gonzalez-Stawinski GV, Budev MM, Mehta AC, McNeill AM, Pettersson GB. Early experience with lung transplantation using donors after cardiac death. J. Heart Lung Transplant. 2008; 27: 561–563.
85. Mason DP, Thuita L, Alster JM, Murthy SC, Budev MM, Mehta AC, Pettersson GB, Blackstone EH. Should lung transplantation be performed using donation after cardiac death? The United States experience. J. Thorac. Cardiovasc. Surg. 2008; 136: 1061–1066.
86. Cypel M, Yeung JC, Keshavjee S. Novel approaches to expanding the lung donor pool: donation after cardiac death and ex vivo conditioning. Clin. Chest Med. 2011; 32: 233–244.
87. Warnecke G, Moradiellos J, Tudorache I, Kuhn C, Avsar M, Wiegmann B, Sommer W, Ius F, Kunze C, Gottlieb J et al. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. Lancet 2012; 380: 1851–1858.
88. Wallinder A, Ricksten SE, Silverborn M, Hansson C, Riise GC, Liden H, Jeppsson A, Dellgren G. Early results in transplantation of initially rejected donor lungs after ex vivo lung perfusion: a case-control study. Eur. J. Cardiothorac. Surg. 2014; 45: 40–44, discussion 4-5.
89. Valenza F, Rosso L, Coppola S, Froio S, Palleschi A, Tosi D, Mendogni P, Salice V, Ruggeri GM, Fumagalli J et al. Ex vivo lung perfusion to improve donor lung function and increase the number of organs available for transplantation. Transpl. Int. 2014; 27: 553–561.
90. Hartwig MG. Is a priori staging of bilateral lung transplant the optimal surgical approach for high-risk patients with interstitial lung disease? J. Heart Lung Transplant. 2014; 32(4S): S30–31.